AUA Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

AUA Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-13	Closed	-$1.52K	–	366
2022 Q3	$1K	Hold	13	–	–	﹤0.01%	323
2022 Q2	$1K	Hold	13	–	–	﹤0.01%	339
2022 Q1	$1K	Hold	13	–	–	﹤0.01%	348
2021 Q4	$1K	Hold	13	–	–	﹤0.01%	330
2021 Q3	$1K	Hold	13	–	–	﹤0.01%	330
2021 Q2	$1K	Buy	13 +1	+8%	+$96	﹤0.01%	318
2021 Q1	$1K	Hold	12	–	–	﹤0.01%	327
2020 Q4	$1K	Buy	12 +3	+33%	+$290	﹤0.01%	322
2020 Q3	$1K	Buy	+9	New	+$1.04K	﹤0.01%	297

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

AUA Capital Management's NBIX Position: Q4 2022 in Review

AUA Capital Management sold out of Neurocrine Biosciences (NBIX) in Q4 2022, closing a stake of 13 shares — an estimated $1.52K sold.

AUA Capital Management first reported a position in NBIX in Q3 2020 and held it in 9 quarters. The position peaked at $1K in Q3 2022. 529 funds tracked by Wall St. Rank hold NBIX as of Q4 2022.

AUA Capital Management reported no remaining Neurocrine Biosciences position as of Q4 2022 after selling out during the quarter.
AUA Capital Management sold 13 Neurocrine Biosciences shares in Q4 2022, an estimated $1.52K.
AUA Capital Management first reported a position in Neurocrine Biosciences in Q3 2020 and held it in 9 quarters.
AUA Capital Management's Neurocrine Biosciences position peaked at $1K in Q3 2022.
529 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2022.

Based on AUA Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.